PMID- 33827139
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 138
IP  - 6
DP  - 2021 Aug 12
TI  - Brentuximab vedotin in combination with nivolumab in relapsed or refractory 
      Hodgkin lymphoma: 3-year study results.
PG  - 427-438
LID - 10.1182/blood.2020009178 [doi]
AB  - This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab 
      (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) 
      classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered 
      dosing of BV and Nivo in cycle 1, followed by same-day dosing in cycles 2 to 4. 
      In part 3, both study drugs were dosed, same day, for all 4 cycles. At end of 
      study treatment, patients could undergo autologous stem cell transplantation 
      (ASCT) per investigator discretion. The objective response rate (ORR; N = 91) was 
      85%, with 67% achieving a complete response (CR). At a median follow-up of 34.3 
      months, the estimated progression-free survival (PFS) rate at 3 years was 77% 
      (95% confidence interval [CI], 65% to 86%) and 91% (95% CI, 79% to 96%) for 
      patients undergoing ASCT directly after study treatment. Overall survival at 3 
      years was 93% (95% CI, 85% to 97%). The most common adverse events (AEs) prior to 
      ASCT were nausea (52%) and infusion-related reactions (43%), all grade 1 or 2. A 
      total of 16 patients (18%) had immune-related AEs that required systemic 
      corticosteroid treatment. Peripheral blood immune signatures were consistent with 
      an activated T-cell response. Median gene expression of CD30 in tumors was higher 
      in patients who responded compared with those who did not. Longer-term follow-up 
      of BV and Nivo as a first salvage regimen shows durable efficacy and impressive 
      PFS, especially in patients who proceeded directly to transplant, without 
      additional toxicity concerns. This trial was registered at www.clinicaltrials.gov 
      as #NCT02572167.
CI  - (c) 2021 by The American Society of Hematology.
FAU - Advani, Ranjana H
AU  - Advani RH
AD  - Stanford University Medical Center, Palo Alto, CA.
FAU - Moskowitz, Alison J
AU  - Moskowitz AJ
AD  - Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Bartlett, Nancy L
AU  - Bartlett NL
AUID- ORCID: 0000-0001-8470-394X
AD  - Department of Medicine, Washington University, St Louis, MO.
FAU - Vose, Julie M
AU  - Vose JM
AUID- ORCID: 0000-0003-1015-7434
AD  - University of Nebraska Medical Center, Omaha, NE.
FAU - Ramchandren, Radhakrishnan
AU  - Ramchandren R
AD  - Karmanos Cancer Institute, Detroit, MI.
FAU - Feldman, Tatyana A
AU  - Feldman TA
AD  - Hackensack University Medical Center, Hackensack, NJ.
FAU - LaCasce, Ann S
AU  - LaCasce AS
AUID- ORCID: 0000-0001-7349-0176
AD  - Dana-Farber Cancer Institute, Boston, MA.
FAU - Christian, Beth A
AU  - Christian BA
AD  - James Cancer Hospital, Columbus, OH.
FAU - Ansell, Stephen M
AU  - Ansell SM
AD  - Mayo Clinic, Rochester, MN.
FAU - Moskowitz, Craig H
AU  - Moskowitz CH
AD  - Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
FAU - Brown, Lisa
AU  - Brown L
AD  - Seagen Inc, Bothell, WA.
FAU - Zhang, Chiyu
AU  - Zhang C
AD  - Seagen Inc, Bothell, WA.
FAU - Taft, David
AU  - Taft D
AD  - Seagen Inc, Bothell, WA.
FAU - Ansari, Sahar
AU  - Ansari S
AD  - Seagen Inc, Bothell, WA.
FAU - Sacchi, Mariana
AU  - Sacchi M
AD  - Bristol-Myers Squibb, Princeton, NJ; and.
FAU - Ho, Linda
AU  - Ho L
AD  - Seagen Inc, Bothell, WA.
FAU - Herrera, Alex F
AU  - Herrera AF
AD  - City of Hope National Medical Center, Duarte, CA.
LA  - eng
SI  - ClinicalTrials.gov/NCT02572167
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 31YO63LBSN (Nivolumab)
RN  - 7XL5ISS668 (Brentuximab Vedotin)
SB  - IM
CIN - Blood. 2021 Aug 12;138(6):421-422. PMID: 34383039
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Brentuximab Vedotin/administration & dosage
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Hodgkin Disease/*drug therapy/*mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nivolumab/administration & dosage
MH  - Recurrence
MH  - Survival Rate
EDAT- 2021/04/08 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/04/07 20:17
PHST- 2020/09/25 00:00 [received]
PHST- 2021/03/18 00:00 [accepted]
PHST- 2021/04/08 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/04/07 20:17 [entrez]
AID - S0006-4971(21)00797-7 [pii]
AID - 10.1182/blood.2020009178 [doi]
PST - ppublish
SO  - Blood. 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178.